# An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits

> **NCT00219245** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 157 (actual)

## Conditions studied

- Traumatic Brain Injury With Persistent Cognitive Deficits

## Interventions

- **DRUG:** Rivastigmine

## Key facts

- **NCT ID:** NCT00219245
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2005-01
- **Final completion:** 2005-01
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2011-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219245, "An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00219245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*